Cytosorbents provides regulatory update for drugsorb-atr

Princeton, n.j., may 1, 2025 /prnewswire/ --  cytosorbents corporation (nasdaq: ctso), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update for drugsorb™-atr, its fda-designated breakthrough device.
ATR Ratings Summary
ATR Quant Ranking